Shanghai Henlius Biotech, Inc. Class H (HK:2696)
:2696
Want to see HK:2696 full AI Analyst Report?
2696 Stock Chart & Stats
HK$84.45
HK$0.05(0.21%)
At close: 4:00 PM EST
HK$84.45
HK$0.05(0.21%)
Day’s Range― - ―
52-Week RangeHK$32.75 - HK$92.00
Previous CloseN/A
Volume849.10K
Average Volume (3M)1.53M
Market Cap
HK$44.97B
Enterprise ValueHK$40.56B
Total Cash (Recent Filing)HK$972.50M
Total Debt (Recent Filing)HK$3.67B
Price to Earnings (P/E)34.6
Beta0.30
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding346,074,400
10 Day Avg. Volume1,665,497
30 Day Avg. Volume1,532,406
Financial Highlights & Ratios
PEG Ratio-17.40
Price to Book (P/B)7.03
Price to Sales (P/S)4.29
P/FCF Ratio32.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$99.12Price Target Upside17.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Profitability & MarginsHenlius has sustained net profitability and high gross margins across 2023–2025, indicating durable product-level economics. For a biologics maker, persistent margins and recurring sales from commercialized therapies support reinvestment in R&D, manufacturing scale, and long-term operating leverage.
Consistent Cash GenerationPositive operating cash flow and recent positive free cash flow demonstrate the company’s ability to convert earnings into cash. This durable cash generation supports capex for GMP capacity, funds product launches and licensing activities, and reduces reliance on volatile external financing over a multi-quarter horizon.
Improving Balance SheetA marked reduction in leverage over several years improves financial flexibility and lowers refinancing and solvency risk. Strengthening equity and solid ROE provide a more stable base to support long-term R&D, manufacturing investments, and potential partnerships or licensing deals without immediate capital strain.
Bears Say
Residual Leverage RiskDespite improvement, meaningful and historically volatile leverage leaves the company sensitive to execution hiccups or slower launches. For capital-intensive biologics development and manufacturing, ongoing leverage can constrain strategic flexibility and increase vulnerability to adverse regulatory or commercial outcomes.
2025 Margin & FCF SofteningMargin compression and a decline in free cash flow in 2025 suggest cost pressures or heavier investment that could persist. If structural (pricing, competition, higher COGS) rather than one-off, these trends can erode the firm’s ability to self-fund growth and weaken long-term earnings power across multiple quarters.
Uneven Cash Conversion HistoryHistorical swings into negative free cash flow show the company’s cash generation is cyclical and linked to heavy investment phases. This unevenness increases the risk that future R&D or capacity expansion cycles could again pressure liquidity or force dilutive financing during periods of strategic spend.
Shanghai Henlius Biotech, Inc. Class H News
2696 FAQ
What was Shanghai Henlius Biotech, Inc. Class H’s price range in the past 12 months?
Shanghai Henlius Biotech, Inc. Class H lowest stock price was HK$32.75 and its highest was HK$92.00 in the past 12 months.
What is Shanghai Henlius Biotech, Inc. Class H’s market cap?
Shanghai Henlius Biotech, Inc. Class H’s market cap is HK$44.97B.
When is Shanghai Henlius Biotech, Inc. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Shanghai Henlius Biotech, Inc. Class H’s earnings last quarter?
Currently, no data Available
Is Shanghai Henlius Biotech, Inc. Class H overvalued?
According to Wall Street analysts Shanghai Henlius Biotech, Inc. Class H’s price is currently Undervalued.
Does Shanghai Henlius Biotech, Inc. Class H pay dividends?
Shanghai Henlius Biotech, Inc. Class H does not currently pay dividends.
What is Shanghai Henlius Biotech, Inc. Class H’s EPS estimate?
Shanghai Henlius Biotech, Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Henlius Biotech, Inc. Class H have?
Shanghai Henlius Biotech, Inc. Class H has 346,074,400 shares outstanding.
What happened to Shanghai Henlius Biotech, Inc. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Shanghai Henlius Biotech, Inc. Class H?
Currently, no hedge funds are holding shares in HK:2696
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Henlius Biotech, Inc. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$99.12 (17.37% Upside)
HK$99.12 (17.37% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
217.03%
12-Months-Change
Fundamentals
Return on Equity
25.67%
Trailing 12-Months
Asset Growth
18.00%
Trailing 12-Months
Company Description
Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. The company also develops Serplulimab to treat squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and solid tumors; HLX04-O, a bevacizumab injection for wet age-related macular degeneration; HLX22 to treat breast and metastatic gastric cancer; HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20 for the treatment of solid tumors; HLX11 to treat breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12 for gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14 to treat osteoporosis. In addition, it develops HLX26 for the treatment of solid tumor and lymphoma; HLX13 to treat melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71 to treat COVID-19. Shanghai Henlius Biotech, Inc. operates in Mainland China, Europe, rest of Asia Pacific, and internationally. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
2696 Stock 12 Month Forecast
Average Price Target
HK$99.12
▲(17.37% Upside)
Technical Analysis
Zai Lab Ltd
―
InnoCare Pharma Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Simcere Pharmaceutical Group Limited
―
Ascentage Pharma Group International
―
Options Prices
Currently, No data available
---